Literature DB >> 11955458

Viral respiratory infection therapy: historical perspectives and current trials.

Jack M Gwaltney1.   

Abstract

Attempts to relieve the misery of the common cold have been made since long before current understanding of its viral origin. Although current symptomatic therapies provide some relief, any effective treatment must incorporate an antiviral to address the infection. Symptom production is related not only to viral cytopathic effect but also to the early activation of several inflammatory pathways. Antiviral treatment alone may not be able to prevent these events. Combining an antiviral with selected therapeutic agents that block these inflammatory pathways has been shown to improve the effectiveness of cold treatment. Early diagnosis and initiation of treatment combined with regular dosing until symptoms subside appears to be the most effective treatment strategy to maximize therapeutic outcomes. This strategy reduces viral shedding in nasal fluid, provides treatment for the period of maximum symptom burden, and may reduce the frequency and severity of the sinus disease that accompanies colds.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11955458     DOI: 10.1016/s0002-9343(01)01062-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

Review 1.  Canadian guidelines for acute bacterial rhinosinusitis: clinical summary.

Authors:  Alan Kaplan
Journal:  Can Fam Physician       Date:  2014-03       Impact factor: 3.275

2.  Canadian clinical practice guidelines for acute and chronic rhinosinusitis.

Authors:  Martin Desrosiers; Gerald A Evans; Paul K Keith; Erin D Wright; Alan Kaplan; Jacques Bouchard; Anthony Ciavarella; Patrick W Doyle; Amin R Javer; Eric S Leith; Atreyi Mukherji; R Robert Schellenberg; Peter Small; Ian J Witterick
Journal:  Allergy Asthma Clin Immunol       Date:  2011-02-10       Impact factor: 3.406

3.  Development of a symptom score for clinical studies to identify children with a documented viral upper respiratory tract infection.

Authors:  James A Taylor; Wendy J Weber; Emily T Martin; Rachelle L McCarty; Janet A Englund
Journal:  Pediatr Res       Date:  2010-09       Impact factor: 3.756

Review 4.  Oral antihistamine-decongestant-analgesic combinations for the common cold.

Authors:  An Im De Sutter; Lars Eriksson; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2022-01-21

5.  The Effectiveness and Safety of a Homeopathic Medicinal Product in Pediatric Upper Respiratory Tract Infections With Fever: A Randomized Controlled Trial.

Authors:  Robert van Haselen; Manuela Thinesse-Mallwitz; Vitaliy Maidannyk; Stephen L Buskin; Stephan Weber; Thomas Keller; Julia Burkart; Petra Klement
Journal:  Glob Pediatr Health       Date:  2016-07-04

Review 6.  Rhinovirus chemotherapy.

Authors:  Amy K Patick
Journal:  Antiviral Res       Date:  2006-04-18       Impact factor: 5.970

7.  Validation of a short form Wisconsin Upper Respiratory Symptom Survey (WURSS-21).

Authors:  Bruce Barrett; Roger L Brown; Marlon P Mundt; Gay R Thomas; Shari K Barlow; Alex D Highstrom; Mozhdeh Bahrainian
Journal:  Health Qual Life Outcomes       Date:  2009-08-12       Impact factor: 3.186

8.  Effects and cost of glycyrrhizin in the treatment of upper respiratory tract infections in members of the Japanese maritime self-defense force: Preliminary report of a prospective, randomized, double-blind, controlled, parallel-group, alternate-day treatment assignment clinical trial.

Authors:  Youichi Yanagawa; Masatsune Ogura; Eita Fujimoto; Satoshi Shono; Eriya Okuda
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

9.  Common cold symptoms in children: results of an Internet-based surveillance program.

Authors:  Emanuel Troullos; Lisa Baird; Shyamalie Jayawardena
Journal:  J Med Internet Res       Date:  2014-06-19       Impact factor: 5.428

Review 10.  Human rhinoviruses: the cold wars resume.

Authors:  Ian M Mackay
Journal:  J Clin Virol       Date:  2008-05-27       Impact factor: 3.168

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.